Skip to main content
OpenTrials
Completed

NCT Number: NCT02758379

Shockwave Coronary Lithoplasty Study

The objective of this clinical trial is to study the early safety and feasibility of the Shockwave Coronary Lithoplasty System. To demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, de novo coronary lesions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Stenosis Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St. Vincent's Hospital Melbourne

Melbourne, Victoria, Australia

About this study

Prospective, non-randomized, single center First In Human (FIH) trial for treatment of stenotic calcified coronary lesions with the Shockwave Lithoplasty System. Patients will be enrolled and consented in the study based on history and in some instances an angiogram obtained prior to the study. The study is designed to demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, coronary arteries. Subjects will be prepared for PCI per the institution's standard protocol. Medications will be administered per the treatment protocol. Femoral access will be obtained using a 6F access sheath, and guiding catheter placed at the ostia of the right or left coronary artery. Baseline angiography of the culprit lesion will be performed prior to placement of a 0.014" guide wire. Baseline and either IVUS or OCT will be performed to determine the Maximum Lumen Area (MLA), percent stenosis, and volumetric lesion assessment. Baseline angiography will be performed to determine lesion length, % stenosis and reference vessel diameter. The investigational device will be prepped per the IFU and positioned at the target lesion. The distal end of the balloon catheter will be connected to the patient cable. The balloon catheter will be inflated to 4 atm and the investigator will deliver 10 pulses for 20 seconds. The balloon will then be inflated to reference vessel diameter and then deflated to reestablish flow and complete one treatment cycle. The treatment cycle will then be repeated. Angiography and either IVUS or OCT will be repeated for the treated lesion.. A coronary stent will be deployed at the site of treatment. Angiography and either IVUS or OCT will be performed following stent placement. Patients will be followed through discharge and at 30 and 180 days. A subset of up to five (5) subjects will receive an angiographic assessment at the 180 day follow up visit, per the Sponsor's discretion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age and able to give informed consent.
  • Patients in Sinus Rhythm.
  • Patients with significant (> 50% diameter stenosis) native coronary artery disease including stable or unstable angina and silent ischemia, suitable for PCI.
  • Ability to tolerate dual antiplatelet agent (i.e. aspirin, clopidogrel or prasugrel). For 1 year and single therapy for life.
  • Patient is able and willing to comply with all assessments in the study.
  • Stenosis of LAD, RCA or LCX artery ≥50% in a reference vessel of 2.5mm-3.5 mm diameter and ≤ 22 mm length, as assessed by two orthogonal angiographic views.
  • Calcification with parallel calcium at least 50% the length of the lesion.
  • At the time of the procedure the subject is in Sinus Rhythm.
  • Single lesions per vessel.
  • Ability to pass a 0.014" guide wire across the lesion.

Exclusion criteria

  • Concomitant use of Rotablator, Cutting Balloon, or investigational coronary devices.
  • Additional planned coronary interventions for a non-target lesion within 180 days of the study procedure.
  • Left ventricular ejection fraction < 40%
  • Patients refusing or not candidates for emergency coronary artery bypass grafting (CABG) surgery
  • Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)
  • Patients who are not candidates for dual anti-platelet therapy for 30 days and chronic single anti-platelet therapy
  • Severe renal failure with creatinine >2.5 mg/dL
  • Untreated pre-procedural hemoglobin <10 g/dL
  • Coagulopathy manifested by platelet count <100,000 or International Normalized ratio (INR) >1.7 (INR is only required in patients who have taken warfarin within 2 weeks of enrollment)
  • Patients in cardiogenic shock
  • Acute myocardial infarction (MI) within the past one (1) month, and/or elevated CPK (and abnormal Troponin-I) at the time of enrollment
  • Patients with a life expectancy of less than 1 year
  • Target main branch vessel < 2.5 mm in diameter
  • Target main branch lesion > 22 mm in length
  • Chronic Total Occlusion (CTO).
  • Previous stent procedure within 10 mm of target lesion
  • Prior PCI procedure within the last 6 months.
  • Target lesion demonstrating severe dissection prior to planned use of the Shockwave device
  • Unprotected Left Main diameter stenosis ≥ 50%
  • Visible thrombus (by angiography) at target lesion site
  • Patient has active systemic infection
  • Patient with an externally-connected intracardiac catheter or pacemaker.
  • Patient with an implantable pacemaker or defibrillator.
  • Patient has connective tissue disease (e.g., Marfan's syndrome)
  • Patient has a hypercoagulable disorder.
  • Patient has allergy to imaging contrast media for which they cannot be pre-medicated.
  • Evidence of aneurysm or acute thrombus in target vessel.
  • Patients with prior sternotomy as a result of thoracic surgery

Treatment and study plan

Shockwave Coronary Lithoplasty System

Device

Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries

Primary outcomes

  1. Safety - Acute, as indicated by number of subjects that do not experience death following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  2. Safety - Acute, as indicated by number of subjects that do not experience tamponade following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  3. Safety - Acute, as indicated by number of subjects that do not experience dissection, occlusion or perforation of the coronary artery that requires additional intervention to treat besides stenting following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  4. Safety - Acute, as indicated by number of subjects that do not experience aneurysm following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  5. Safety - Acute, as indicated by number of subjects that do not experience MI (CPK > 5 x uln) following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  6. Safety - Acute, as indicated by number of subjects that do not experience cardiogenic shock following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  7. Safety - Acute, as indicated by number of subjects that do not experience distal embolization compromising blood flow, and requiring intervention following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  8. Safety - Acute, as indicated by number of subjects that do not experience blood transfusion due to excessive blood loss following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  9. Safety - Acute, as indicated by number of subjects that do not experience stroke following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

  10. Safety - 30 days (Number of subjects without any procedure and/or device related adverse events)

    Time frame: 30 days post procedure

  11. Safety - 30 days (Number of subjects without target lesion revascularization (TLR)

    Time frame: 30 days post procedure

  12. Safety - 30 days (Number of subjects without groin complications)

    Time frame: 30 days post procedure

  13. Safety - 180 days (Number of subjects without any procedure and/or device related adverse events)

    Time frame: 180 days post procedure

  14. Safety - 180 days (Number of subjects without any target lesion revascularization (TLR))

    Time frame: 180 days post procedure

  15. Performance - Acute technical success of the device

    Time frame: Post-procedure (within 24 hours following procedure)

    • Successful delivery of the device and administration of lithotripsy-enhanced low pressure balloon dilation to the target lesion
    • Residual stenosis of ≤50% of the reference vessel size of the target lesion assessed by angiography and either IVUS or OCT.
    • Successful access of the treatment site with a coronary stent

  16. Safety - Acute, as indicated by number of subjects that do not experience ventricular arrhythmic event requiring intervention to re-establish normal rhythm following delivery of shockwave energy

    Time frame: Post-procedure (within 24 hours following procedure)

Sponsors and collaborators

Lead sponsor

Shockwave Medical, Inc.

Industry

Collaborators

  • Massachusetts General Hospital
  • Pacific Clinical Research Group
  • Yale Cardiovascular Research Group

Registry information

Official study title

Early Safety and Feasibility Study of the Shockwave Coronary Lithoplasty™ System in Coronary Arteries

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
May 2, 2016
Registry last updated
Jul 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.